De-intensification of adjuvant therapy in human papillomavirus-associated oropharyngeal cancer. Cancers of the head & neck An, Y., Holsinger, F. C., Husain, Z. A. 2016; 1: 18

Abstract

Current adjuvant treatment guidelines for oropharyngeal squamous cell carcinoma treated with primary surgery are based on studies that predate the human papillomavirus (HPV) era. HPV-associated oropharynx carcinoma (HPV-OPC) has a much more favorable prognosis compared to HPV-unassociated cancer and is increasingly considered to be a distinct disease entity due to its unique etiology, presentation, and behavior. Currently, there is significant interest in adjuvant treatment de-intensification of HPV-OPC patients in order to reduce treatment-related toxicity while maintaining excellent clinical outcomes. Here, we review the evidence and rationale underlying the ongoing prospective trials of adjuvant treatment de-intensification for HPV-OPC patients.

View details for DOI 10.1186/s41199-016-0016-7

View details for PubMedID 31093347

View details for PubMedCentralID PMC6460758